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We describe the successful treatment of an infant with life-threatening KasabacheMerritt syndrome
(KMS) who received propranolol therapy. A full-term, 6-week-old female infant, in poor general con-
dition, was admitted with a large vascular tumor of right buttock, perineal region, extending to a lumbar
region and the right thigh. There was a gray-blue, tense, shiny, warm swelling over the site of vascular
tumor. The child had platelet count of 20,000 cells/mm. D-dimer was positive and suggestive of
consumptive coagulopathy. A diagnosis of KMS was made. Computer tomography (CT) imaging was
suggestive of a vascular tumor e Kaposiform hemangioendothelioma. The baby was initially treated with
platelet, fresh frozen plasma and blood transfusions. There was temporary rise in platelets to
118,000 cells/mm but after transfusions the platelets dropped to 20,000 cells/mm and the baby devel-
oped purpuric swelling over right thigh and right buttock. Platelet transfusions were discontinued and
propranolol treatment was started. From the 4th day, the swelling started regressing and the platelet
count rose to 73,000 cells/mm. At the age of 2 years, the tumor has nearly completely involuted. In our
case propranolol proved to be effective ﬁrst-line treatment for KasabacheMerritt syndrome associated
with a vascular tumor e Kaposiform hemangioendothelioma. Minor side effect was poor weight gain
after prolonged treatment.
 2013 Elsevier Inc. Open access under CC BY-NC-ND license.Vascular tumors in the pediatric age group e usually are in- perineal region, extending to a lumbar region and the right thigh.
fantile hemangiomas (IH) e common, benign tumors, occurring in
4e10% of infants [1]. A signiﬁcant proportion of vascular tumors are
associated with substantial morbidity in infancy and childhood [2].
KasabacheMerritt syndrome (KMS) is a potentially life-threatening
coagulopathy characterized by enlarging hemangioma with severe
thrombocytopenia [3], quite rarely associated with infantile hem-
angiomas, in most cases e associated with Kaposiform hemangio-
ma or tufted angiomas [4]. The consumption coagulopathy occurs
due to endothelial defects within the hemangioma causing platelet
activation, platelet-ﬁbrin thrombosis formation, consumption of
clotting and coagulation factors, and increased ﬁbrinolysis [5].
Although propranolol now is widely used for the treatment of
complicated IH, no uniformly accepted protocol exists regarding the
administration of oral propranolol for KMS associated with Kapo-
siform hemangioma or tufted angiomas.
1. Case report
A full-term, 6-week-old female infant, in poor general condition,
was admitted to our Department, with a large IH of right buttock,þ48 857450920.
-NC-ND license.On examination there was a gray-blue, tense, shiny, warm swelling
over the right buttock, perineal region, extending to the waist and
upper one-third of the right thigh Fig. 1. An ultrasound had shown a
heterogeneous mass with increased vascularity involving subcu-
taneous plane. Computer tomography (CT) imaging was suggestive
of a vascular tumor e Kaposiform hemangioendothelioma. This
tumor has unique histologic and radiologic ﬁndings. Although we
did not have histologic conﬁrmation of the diagnosis, we made the
clinical diagnosis of the KasabacheMerritt phenomenon, caused by
a vascular tumor e Kaposiform hemangioendothelioma. A radio-
graph of the pelvis showed no bony abnormality. The ultrasono-
gram of the abdomen and echocardiogramwere normal. There was
no distal neurovascular deﬁcit. The child was icteric with a platelet
count of 20,000 cells/mm. Hemoglobin level was 8.7 g/dl. D-dimer
was positive and suggestive of consumptive coagulopathy. The
coagulation proﬁle was deranged (prothrombin time 15 s, activated
partial thromboplastin time 48.7 s). Fibrinogenwas low (103 mg/dl,
normal 180e450mg/dl). A diagnosis of KMSwith IH was made. The
baby was initially treated with platelet, fresh frozen plasma and
blood transfusions. There was temporary rise in platelets to
118,000 cells/mm but after transfusions of three units of platelet
concentrates the platelets dropped to 20,000 cells/mm and the
baby developed purpuric swelling over right thigh and right
Fig. 1. Vascular tumor associated with KasabacheMerritt syndrome (KMS) in 6-week
old female.
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platelet transfusion was considered. Hence, platelet transfusions
were discontinued and propranolol was started at a dose of 1 mg/
kg. During three consecutive days dosage was gradually increased
to 3 mg/kg. From the 4th day, since propranolol was started, the
swelling started regressing and the platelet count rose to
73,000 cells/mm. The hemangioma slowly diminished in size. After
3 weeks of treatment, laboratory datawere normal, and the girl was
discharged home. During ambulatory surveillance of the girl, po-
tassium, sodium, chlorine, glucose, liver enzymes, morphology,
vital signs and electrocardiography (ECG) were monitored. The
main side effect was poor weight gain. At the age of 8 months,
child’s weight was 10 kg (25pc). Because of the fact above the dose
of propranolol was reduced to 2 mg/kg. After a week, sudden
growth of the hemangioma was noticed. Again the dose was raised
to 3 mg/kg. At the age of 1 year again the dosage was reduced to
2 mg/kg, at the age of 14 months reduced to 1 mg/kg, at the age of
16 months reduced to 0.5 mg/kg. The treatment was terminated at
the age of 18 months. During ambulatory treatment we didn’t
notice other adverse effects e.g., hypotension, bradycardia, hypo-
glycemia and bronchospasm. At the age of 2 years, the tumor has
nearly completely involuted, child’s weight reached 50pc Fig. 2.Fig. 2. Girl at the age of 2 years 6 months after successful treatment with propranolol.2. Discussion
Vascular tumors in pediatric age group can have life-threatening
complications including severe thrombocytopenia as part of KMS
[1e3,5]. Hemangioma associated with thrombocytopenia in aninfant (KMS) was ﬁrst described by Kasabach and Merritt in 1940
[3]. Nowadays we know, that KMS occurs in approximately 0.3% of
infants with Kaposiform hemangioma or tufted angiomas. Mortal-
ity rates of 10e37% have been reported resulting from hemorrhage,
infection, invasion of vital structures, and multiple organ failure
[1,6]. The goal of treating KMS associated with Kaposiform hem-
angioma or tufted angiomas is to control the thrombocytopenia and
avoid the lethal complications. Currently, there are no known
treatment guidelines for KMS [5]. Several multimodality regimens
have been described but with variable success and many side
effects. Pharmacological treatments include systemic corticosteroid
therapy, interferon therapy, anticancer drugs, and antiplatelet
therapy. Supportive therapies include fresh frozen plasma (FFP) and
platelet transfusions. Patients with high-output cardiac failure need
management to avoid further cardiac compromise [1e3,5].
High-dose prednisolone (2 mg/kg/day) therapy was reported to
be successful in some cases of KMS, but was ineffective in other
reported cases [7]. Corticosteroids have antiangiogenic properties,
facilitating intralesional thrombosis by inhibiting ﬁbrinolysis.
Nonetheless, it is not unusual that vascular tumors increase in size
after steroids arewithdrawn, so thatmultiple courses of therapy are
necessary. In contrast to the excellent steroid response rate for skin
hemangiomas (90%), a similar result has not been reported for KMS
(30e50%) [5,8,9]. Side effects associated with steroid treatment
include hypertension, cushingoid appearance, growth suppression
and opportunistic infections [9]. Interferon alpha2b therapy re-
mains controversial, with a response rate of about 50% [10,11]. The
adverse effects of interferon therapy include ﬂu-like symptoms,
neutropenia, and spastic diplegia in infancy [11]. Vincristine is
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platelet count and signiﬁcant decrease in the vascular tumor size in
patients treated with vincristine, but complications included
abdominal pain, irritability, and transient loss of deep tendon re-
ﬂexes [12]. Heparin and antiplatelet therapy have been reported to
have varied success [7]. Surgical resection can be deﬁnitive treat-
ment for KMS, but in most cases is not possible because of the
location and size of the vascular tumor, moreover patient must be
hematologically stable [7,13]. Another option is transarterial
embolization, and successful treatment of KMS with embolization
has been reported with several embolic materials, such as coils,
polyvinyl alcohol (PVA), and onyx [7]. Large review of 153 reported
cases in 33 published articles undertaken by El-Dessouky showed
that the combination of radiation therapy with corticosteroid
therapy produced the best results in the treatment of KMS and was
superior to surgery or corticosteroid therapy alone [14]. The
mechanism of action of radiotherapymay be related to inhibition of
cellular proliferation in vascular endothelial cells. The main prob-
lem with the use of radiotherapy for KMS is the risk of late effects
and carcinogenesis. In Mitsuhashi’s series, three patients who
received multiple courses of radiation were left with shortening of
the involved extremity [15]. A total of 248 malignancies were
recorded in the Swedish Cancer registry till 1989, in patients with
vascular tumors treated with brachytherapy between 1930 and
1965 [16].
In 2008, Leaute-Labreze et al. reported the incidental ﬁnding
that IH regress in children treated with propranolol, a nonselective
beta-blocker used in treating infants with cardiac and renal con-
ditions [17]. In most case reports, propranolol was not used as
single therapy of IH, as patients received concomitant systemic or
intralesional steroids and laser treatment [18]. Schiestl et al. in their
study included only infants with IH treated exclusively with pro-
pranolol at a dose of 2 mk/kg/day, and in all patients there was a
signiﬁcant cosmetic improvement [1]. In cases reported by Aru-
nachalam propranolol treatment was combined with steroids, in
case reported by Hermans propranolol was combined with
vincristine treatment [19,20]. Variable response to propranolol
treatment of Kaposiform hemangioendothelioma, tufted angioma,
and KasabacheMerritt phenomenon was described by Chiu et al.
who reports on 11 patients treated with propranolol for Kaposiform
hemangioendothelioma and the related variant tufted angioma, six
of whom also had KMS [21]. In our patient there was a dramatic
response in the platelet count with nearly complete regression of
the tumor after commencing propranolol.
The effect of propranolol on vascular tumors such as Kaposiform
hemangioma or tufted angiomas and KMS can be attributed to
molecular mechanisms: vasoconstriction, decreased expression of
vascular endothelial growth factor (VEGF) and basic ﬁbroblast
growth factor (bFGF) genes through the down-regulation of the
RAF-mitogen-activated protein kinase pathway, inhibition of
angiogenesis, and induction of apoptosis [1,19]. Treatment with
propranolol may cause severe systemic complications and infants
need to be closely monitored [17,18]. During propranolol therapy of
our patient, potassium, sodium, chlorine, glucose, liver enzymes,
morphology, vital signs and ECG were monitored. The most com-
mon reported side effects of propranolol include hypotension,
bradycardia, hypoglycemia and bronchospasm [4,17,18,20]. More-
over propranolol maymask the clinical signs of early cardiac failure,
diminish cardiac performance, and blunt clinical features of hypo-
glycemia. Prolonged hypoglycemia in infancy is associated with
neurologic sequelae [20]. Despite of high dosage of propranolol
(3 mg/kg/day), the only side effect in our patient was poor weight
gain during prolonged treatment. During ambulatory surveillancewe did not observe hypoglycemia, hypotension or adverse cardiac
effects. The treatment was well tolerated and has long-lasting
effects. At the age of 2 years, 6 months after the end of propranolol
treatment, the tumor has nearly completely involuted, child’s
weight reached 50pc.3. Conclusion
In our case, propranolol proved to be effective ﬁrst-line treat-
ment for KMS associated with a vascular tumor e Kaposiform
hemangioendothelioma. Minor side effect was poor weight gain
during prolonged treatment.
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